How the body keeps antibody-making cells alive
Biochemical Mechanisms for Sustained Humoral Immunity
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-11284113
This project looks at signals that help long-lived antibody-producing cells survive, which could affect people with infections, vaccine responses, or antibody-driven diseases.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11284113 on ClinicalTrials.gov |
What this research studies
From the patient's perspective, researchers are focused on plasma cells in the bone marrow that make antibodies for years. They will study how these cells sense extracellular ATP through a receptor called P2rX4 and how nearby bone-forming cells may release ATP via a channel called Panx3. The team will manipulate P2rX4 and Panx3 in laboratory models and in cell and tissue samples to see how those changes alter plasma cell survival and blood antibody levels. Results will map both cell-intrinsic and external signals that keep long-lived plasma cells functioning.
Who could benefit from this research
Good fit: People with antibody-driven autoimmune conditions, those with unusually weak or short-lived vaccine responses, or volunteers willing to donate blood or bone marrow samples would be most relevant to this research.
Not a fit: Patients whose conditions are unrelated to antibody-producing plasma cells or who need immediate clinical therapies are unlikely to receive direct benefit from this basic science work.
Why it matters
Potential benefit: If successful, this work could point to ways to reduce harmful long-lived antibodies in autoimmune disease or to strengthen lasting antibody responses after vaccination.
How similar studies have performed: Related laboratory studies show purinergic signaling can affect immune cells, but targeting P2rX4/Panx3 in long-lived plasma cells is a novel approach with limited prior clinical testing.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ALLMAN, DAVID M — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: ALLMAN, DAVID M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.